A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
← catalyst calendarNCT07677059 · readout ≤ 865 d
Sponsored by Kymera Therapeutics, Inc. (industry) · KYMR — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
264estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jul 2026 | estimated | When the study began enrolling |
| Primary completion | Dec 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma (Diagnosis)
Intervention
- Drug: KT-621
Primary outcomes
what the primary-completion date above is the date OFIncidence of treatment-emergent adverse events (TEAEs)
measured From baseline through Week 52
Incidence of treatment-emergent serious adverse events (SAEs)
measured From baseline through Week 52
Permalink · KYMR's whole pipeline · Catalyst calendar · Every registered study · What changed